Amerikanische Gesellschaft für Hirudotherapie

Bivalirudin in acute coronary syndromes

Research article published in Expert review of cardiovascular therapy (2023)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienArzneimittelentwicklungSicherheit & InfektionskontrolleSpeichel-PharmakologieGalli M et al. · Expert review of cardiovascular therapy, 2023

Abstract

INTRODUCTION: Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). AREAS COVERED: Despite showing a superior safety profile compared with unfractionated heparin (UFH), bivalirudin is not considered the anticoagulant of choice in ACS patients undergoing PCI, mainly because of an increased rate of acute stent thrombosis (ST) shown by several randomized controlled trials (RCTs), in addition to limited availability in certain countries and increased costs. However, RCTs on bivalirudin have been characterized by several confounding factors hindering the interpretation of its safety and efficacy compared with UFH among the spectrum of ACS patients. Furthermore, a significant body of evidence has demonstrated that the risk of acute ST can be mitigated by a full-dose infusion regimen following PCI, without compromising the favorable safety profile compared to UFH. EXPERT OPINION: In light of the increased understanding of the prognostic relevance of bleeding events and the excellent safety profile of bivalirudin, recent trial evidence may allow for this anticoagulant agent to reemerge and have a more prominent role in the management of ACS patients undergoing PCI.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansAcute Coronary SyndromeTreatment OutcomeHirudinsHeparinAntithrombinsAnticoagulantsPeptide FragmentsHemorrhagePercutaneous Coronary InterventionRecombinant Proteins

Zusammenfassung

Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).

Warum dies für die Hirudotherapie relevant ist

This article reviews the role of bivalirudin, a bivalent direct thrombin inhibitor, in acute coronary syndrome patients undergoing percutaneous coronary intervention, discussing its safety profile relative to unfractionated heparin, the issue of acute stent thrombosis, and how infusion regimens may mitigate that risk. It suggests bivalirudin may reemerge as a relevant anticoagulant in ACS management. The abstract contains no mention of leeches, hirudotherapy, hirudin as a leech-derived substance, or the leech secretome. The only potential link to ASH's domain is the shared MeSH indexing term 'Hirudins'; the article itself provides no substantive relevance to hirudotherapy or the leech secretome.

Zitation

Bivalirudin in acute coronary syndromes

Galli M et al. · Expert review of cardiovascular therapy, 2023

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsSafety ProtocolsAeromonas ManagementSalivary Gland SecretionAnti-Inflammatory MechanismsSalivary ComplexHirudinAnticoagulation CompoundsBivalirudinHemostasisDermatological ApplicationsDermatologyOtolaryngologyPost-Thrombotic Syndrome

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.